Integra LifeSciences Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Wells Fargo Upgrades Integra LifeSciences (IART) to Outperform
May 1, 2015 6:48 AM EDTWells Fargo upgraded Integra LifeSciences (NASDAQ: IART) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.
Shares of Integra LifeSciences closed at $58.78 yesterday.
... MoreIntegra LifeSciences (IART) Appoints New CEO
April 30, 2015 4:28 PM EDTIntegra LifeSciences (NASDAQ: IART) announced the appointment, effective May 1, 2015, of Keith Valentine as Chief Executive Officer of SeaSpine Holdings Corporation, which will be an independent, publicly traded company following the completion of its spin-off from Integra. SeaSpine, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, located in Vista, CA, has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions.
"With more than 20 years of experience in the orthopedic industry and an outstanding track record of success, Keith's proven leadership skills will drive growth and innovation at... More
Integra LifeSciences (IART) Tops Q1 EPS by 13c
April 30, 2015 4:27 PM EDTIntegra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.76, $0.13 better than the analyst estimate of $0.63. Revenue for the quarter came in at $233.7 million versus the consensus estimate of $229.69 million.
Integra LifeSciences sees FY2015 EPS of $3.15-$3.33, versus the consensus of $3.17. Integra LifeSciences sees FY2015... More
